Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Liabilities and Shareholders Equity (2023 - 2025)

Immunome (IMNM) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $683.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 184.38% year-over-year to $683.2 million, compared with a TTM value of $1.6 billion through Dec 2025, up 45.68%, and an annual FY2025 reading of $683.2 million, up 184.38% over the prior year.
  • Liabilities and Shareholders Equity was $683.2 million for Q4 2025 at Immunome, up from $299.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $683.2 million in Q4 2025 and bottomed at $41.4 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $255.5 million, with a median of $276.6 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity surged 614.89% in 2024, then rose 0.03% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $148.5 million in 2023, then soared by 61.73% to $240.2 million in 2024, then surged by 184.38% to $683.2 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for IMNM at $683.2 million in Q4 2025, $299.4 million in Q3 2025, and $296.3 million in Q2 2025.